Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
THATS PHOTOTRON!
Skip Skip Skip Just be patient
Gold is at almost $1800 an ounce now and expected to go to $3500
This is info from Sunbiz.org an State of Florida official Website. It is posted on Sunshines box in the upper IBOX section
It was ratified in 2019 no other amendment was listed after this except for the reinstatement document. I would think if it is canceled you would find it among the list on the Florida State official site. I wouldn't give up my shares to no one. If this is the case our shares are worth much much more. Thanks for putting in IBOX Sunshine Just my honest opinion.
http://search.sunbiz.org/Inquiry/CorporationSearch/ConvertTiffToPDF?storagePath=COR%5C2019%5C0226%5C24614137.Tif&documentNumber=P05000066269
I have to tell you : data came from IHUB Let’s see if you can fix that? One of our moderates had to put that data on. You think they got hacked too?
Thanks!
Data was there Looks like the data created a new tweet Lets see what else you know
No this is what is listed on the filings with the reinstatement
.
sunbiz.org/Inquiry/CorporationSearch/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=WORLDOILGROUP P050000662693&aggregateId=domp-p05000066269-4fb2ff81-5d9d-45dc-a189-116ef26bb484&searchTerm=world oil group&listNameOrder=WORLDOILGROUP P050000662693
Are you saying none of this is true?
Sorry it was 100,000 -1 arch.sunbiz.org/Inquiry/CorporationSearch/ConvertTiffToPDF?storagePath=COR\2019\0226\24614137.Tif&documentNumber=P05000066269
in 2019 they had a 10-1 reverse split also
Birkshire bought out Dominion Energy today. They are from Virgina. Who knows. I'm sure we will find out something soon
If they can get a $100 million loan you have to wonder just how much they are really worth. :.)
Hold on Jimmy! Looks like there is more to come:.)) IMHO
I thought it was already EU approved?
10 mill vol and not even noon yet ;.)))))
Another 911 signal MMmmmmm
The new article does explain that and this. Just thought you would like to know
Lets hope
Or maybe covering for the biggest culprit? Two sides to every story. I trust no one. Lay faith to none of these appointments. All of these appointments have either went to jail or fired. The man behind the curtain is running things. Be surprised by nothing. Not even you will come out ahead before the man behind the curtain.
Probably the news that was signaled yesterday. Good news and quite a surprise. Thanks for sharing
There went the 911 signal
Volume drying up. I am guessing there will be an upturn soon.:.)
It was also on Wednesday last week also
Me too
Lunch time and the volume hasn't hit 1 mil yet. I think the spring is tight. Not much more that they can do to manipulate.
I agree. The volume is back to normal They are at the end of their ability to move this stock without losing their own money JMHO
Probably ;.)
Where did everyone go?
NEWS
GrowLife, Inc. Reports Increase in Quarter-Over-Quarter Revenue and Gross Margins in Q1 2020 Financial Results Filing
[GlobeNewswire]
GlobeNewswireMay 29, 2020
Company Files Quarterly Report on Financial and Operations Results from the Period Ending March 31, 2020
Summary:
GrowLife experienced revenue growth of 12.8% quarter-over-quarter in first quarter of 2020 as compared to the fourth quarter of 2019, from $1,473k to $1,661k.
GrowLife increased its blended gross margins to 39.3% for the period ending March 31, 2020, up from the fourth quarter of 2019 and last year’s overall which were 24.2% and 31.0% respectively.
GrowLife reported a $400k sales order backlog, not included in revenue, to be shipped in the second quarter of 2020.
GrowLife reduced operating expenses for the period ending March 31, 2020 by $772,000 when compared to the same period in 2019.
GrowLife focused on the market opportunity of selling hemp clones through its newly established brand “EZ-CLONEZ” which sells exclusive strains of CBD-rich hemp clones.
GrowLife continued to operate and provide essential business services on a state-by-state basis throughout the COVID-19 pandemic.
KIRKLAND, Wash., May 29, 2020 (GLOBE NEWSWIRE) -- GrowLife, Inc. (PHOT) (“GrowLife” or the “Company”), one of the nation’s most recognized indoor cultivation product and service providers, today announced financial results for the period ending March 31, 2020 and provided some recent operational highlights.
The Company reported growth in its revenue over the last quarter, reporting $1,661k for the period ending March 31, 2020, an increase of 12.8% quarter-over-quarter. Additionally, with a continued focus on increasing profitability, the company reported increased gross margins of 39.3%, in comparison to the fourth quarter 2019 which were 24.3% and last year’s overall 31%. As a result of the cost reductions implemented in 2019, the Company reduced operating expenses by $772k and cash used in operations by $694k during the period ending on March 31, 2020 when compared to the same period in 2019.
“Most importantly, we continued to operate and show growth amidst the COVID-19 pandemic and provide essential products and services to the hemp and cannabis industries which recently saw even greater support from the states,” said GrowLife CEO Marco Hegyi. “Our entrance into the CBD-rich clone space has created a whole new market opportunity for GrowLife to capitalize on our high-margin EZ-CLONE business. While this quarter presented unprecedented challenges, our team was able to increase revenue over last quarter and continue to service the CBD industry, which continues to rapidly expand where other industries have experienced downturns. We continue to see the greatest opportunity in positioning ourselves as the industry leader in plant cloning, and more specifically, as the leader in cloning of hemp plants grown for CBD extraction.”
“We believe that with the revenue growth and increased margins we reported in the first quarter, that our fundamentals are strong, our positioning is focused, and our trajectory is encouraging. To put it is simply, we are ready and prepared to make our place in one of the largest shifts in mainstream wellness and agriculture in history,” added Hegyi.
Q1 2020 FINANCIAL RESULTS
Net Revenue: For the period ending March 31, 2020, GrowLife showed net revenue of $1,661,000, as compared to revenue of $1,473,000 for the period ending December 31, 2019 – an increase of 12.8%.
Gross Profit: For the period ending March 31, 2020, GrowLife had Gross Profit of $653,445 as compared to $356,000 for the period ending Dec. 31, 2019 – an increase of approximately 83.3%.
Net Loss: For the period ending March 31, 2020, GrowLife had a Net Loss of $1,293,675 as compared to a loss of $2,338,325 for the period ending March 31, 2019.
Cash Flow used in Operations: For the period ending March 31, 2020, GrowLife had Cash Flow Used in Operations of $422,780 as compared to $1,116,717 for the period ending March 31, 2019.
About GrowLife, Inc.
GrowLife, Inc. (PHOT) aims to become the nation’s largest cultivation service provider for cultivating organics, herbs and greens and plant-based medicines. Our mission is to help make our customers successful. Through a network of local representatives covering the United States and Canada, regional centers and its e-Commerce team, GrowLife provides essential goods and services including media, industry-leading hydroponics and soil, plant nutrients, and thousands of more products to specialty grow operations. GrowLife is headquartered in Kirkland, Washington and was founded in 2012.
Public Relations Contact:
CMW Media
Tooo far
You silly. You can't bid that far away from share price. It has been a rule for a long time
To give you personally info that wasn't available to public would probably get them in trouble? Right? And I'm sure if they would have given this info to someone other than yourself you would have pleaded that very case. Right?
Thanks for sharing Rusty. Looking good
Siemens is a very good company to be interested and willing to help coordinate the nano particle with the MRI's. Not only will the screening improve but it will work with existing equipment. JMHO
Seiemens! This is Very Good News! Can be used with existing equipment.
Imagion Biosystems establishes collaboration with Siemens Healthineers
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announces it has entered into a collaboration agreement with Siemens Healthcare Pty Ltd of Australia (Siemens Healthineers) to further explore the utility of Imagion’s MagSense™ nanoparticles as an MRI contrast agent.
The collaboration will see Siemens Healthineers work with Imagion to identify optimal MRI scanning protocols for the MagSense™ HER2 targeted nanoparticles. Siemens Healthineers in-kind contribution of expertise and provision of technical support to clinical sites will be valuable should Imagion undertake a study in Australia which includes MRI scans.
Imagion has previously announced that it is planning for its first clinical study of the MagSense™ technology in HER2 breast cancer patients. The MagSense™ nanoparticles are designed to be detectable only when attached to cancer cells providing a specific means of cancer imaging, and has a received Breakthrough Device designation from the US Food and Drug Administration (FDA). The collaboration with Siemens is in line with Imagion’s strategy to explore an additional and alternative use of the MagSense™ nanoparticles as an MRI contrast agent.
Imagion Biosystems presented its first data showing that the MagSense™ nanoparticles could be used as a magnetic resonance imaging agent, at the World Molecular Imaging Conference in September 2019. This collaboration establishes a path for Imagion to further explore MRI as a commercial pathway leveraging the large global installed base of existing MRI scanners.
Contrast agents are used to enhance the image and improve resolution. To-date, imaging agents have been general purpose, creating contrast at tissue boundaries but not providing functional imaging utility. A targeted MagSense™ nanoparticle could be used as a contrast agent to enhance an MR image of specific diseased tissue, thus providing a clear and accurate method to use imaging to non-invasively detect cancer with existing imaging technology.
“We are very pleased to have Siemens Healthineers offer of assistance as we look at all the possibilities to develop and commercialize our technology,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “The ability to use a targeted contrast agent like ours, in the MRI setting, could transform the way MRI is used to diagnose cancer and other diseases. In entering into this collaboration, we will jointly gain insight into the clinical and commercial potential of our novel technology. We are proud that Imagion continues to attract the support of leading industry players and opinion leaders.”
“Siemens Healthineers has a strong focus on expanding Precision Medicine and transforming care delivery,” said Dr Kieran O’Brien, Head of Collaborations and Research for Australia and New Zealand for Siemens Healthcare Pty Ltd, “Imagion’s targeted contrast technology MagSense™ could offer patients a more specific means to monitor cancer with MRI, and we look forward to assisting Imagion in investigating the application of their technology with MRI scanners.”
Siemens Healthineers is a leading medical technology company. With over 120 years of experience, Siemens Healthineers is enabling healthcare providers to increase their value through digitalised healthcare. Siemens Healthineers portfolio of products and services is largely compromised of its core areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine.
-ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
This Announcement has been approved by the Disclosure Committee of Imagion Biosystems Limited
For further information please visit www.imagionbiosystems.com
Australian Media & Investor Relations
Kyahn Williamson, WE Communications
we-AUimagionbiosystems@we-worldwide.com
+61-3-9866-4722
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Well Well Well: Looks like we have an investor that just bought 5.8% of PMCB ;.) Schedule 13D filed yesterday: I'm sure they don't plan or expect their investment to fail.
https://ih.advfn.com/stock-market/USOTC/pharmacyte-biotech-qb-PMCB/stock-news/82394813/statement-of-beneficial-ownership-sc-13d
All these lemons being thrown around is going to make an awful lot of lemonade ;.)
Bingo! News for all you naysayers
PharmaCyte Biotech Receives Medical Devices Registration and Submits Pre-EUA Application to the FDA for COVID-19 Diagnostic Kit
May 06, 2020 07:30 AM Eastern Daylight Time
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received Medical Devices Establishment Registration with the FDA’s Center for Devices and Radiological Health (CDRH). The CDRH requires this registration for companies that plan to import medical devices from overseas suppliers. The company also established itself as the sole U.S. agent for Hai Kang Life Corporation Limited (Hai Kang) for the importation of SARS-CoV-2 in vitro diagnostic test kits. The company plans to market its PCR-based diagnostic tests kits to Clinical Laboratory Improvement Amendments (CLIA) certified labs throughout the United States.
The company also announced that it is in dialogue with the U.S. Food and Drug Administration (FDA) through a Pre-Emergency Use Authorization (EUA) submission to the FDA. An EUA is a legal means for the FDA to expeditiously approve new drugs and new medical devices during a declared national emergency. For COVID-19 diagnostic test kits, the FDA recommends that manufacturers and suppliers file a Pre-EUA with the FDA in order to interactively work towards an eventual EUA submission and approval by the FDA. The FDA encourages companies to file an early draft so that the FDA examiner can offer feedback to avoid delays during the review of the final EUA application.
Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte Biotech, stated, “We have satisfied all of the regulatory requirements to get our COVID-19 diagnostic test kits into the country and are actively working with our partner, Hai Kang, through the FDA’s preferred process of a Pre-EUA submission, dialoguing with our assigned examiner towards a final EUA submission to and approval by the FDA.”
About PharmaCyte Biotech
PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. In addition, PharmaCyte is developing and preparing to obtain approval from the U.S. FDA to commercialize a Covid-19 diagnostic kit to meet a critical unmet medical need for such kits during the current pandemic.
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.
PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is developing the use of genetically modified liver cells and stem cells, as well as beta islet cells, to treat diabetes. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.
PharmaCyte’s diagnostic test kits, which were developed by and licensed from Hai Kang Life Corporation Limited (Hai Kang), for detecting the SARS-CoV-2 virus is the Enhanced Real-Time PCR (ERT-PCR) method. The technology is the same as the previous test for the SARS outbreak in 2003 that was published in the New England Journal of Medicine, but the primers and probes used in the current test is specific for the novel coronavirus. This means test results are positive only if the SARS-CoV-2 target sequences are present in the test sample.
Safe Harbor
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte, including statements regarding the viability of the technology that is the subject to the Hai Kang License Agreement (Agreement) with PharmaCyte, our ability to gain the necessary approvals to market and commercialize Products under the Agreement, and the timing and commencement of such commercialization. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward- looking statements. Factors that could affect our actual results include our ability to raise the necessary capital to fund our operations and to find partners to supplement our capabilities and resources, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward- looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise
More information about PharmaCyte can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.
Contacts
Dr. Gerald W. Crabtree
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
Thanks for your input here. I do appreciate it. (psst: did you notice hunch left an s off of lets)Hehehehe
Well here is the volume 4 times normal. :.)